How quickly does Wegovy start working — and what actually happens first?

The biggest misconception: Wegovy should be working by week two

One of the most common misunderstandings about Wegovy is that early results should be dramatic. People start the first pen, feel less hungry than usual, and expect the scales to follow immediately. When they don't shift much, doubt sets in. The truth is that Wegovy's starting dose (0.25 mg) is not a therapeutic weight-loss dose at all. It exists specifically to let your system adjust gradually, reducing the chance of nausea and other gastrointestinal side effects that are more likely at higher doses. Think of those first four weeks as your body learning to tolerate the medicine, not as the treatment phase.

The titration schedule then steps up roughly every four weeks: 0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, and finally 2.4 mg maintenance, meaning most people don't reach the full dose until around week 17 at the earliest. If you're wondering how quickly Wegovy works in practice, weight loss that feels significant is most likely to begin accelerating from the 1.0 mg stage onwards. Our Wegovy treatment page describes the dosing pathway in more detail.

So if you're at week two wondering why nothing has happened, the answer is almost certainly: the treatment hasn't started in earnest yet. That's not a failure, it's how the medicine is designed. Patience at this stage isn't passive; it's the right clinical approach.

What actually changes first, and when weight loss tends to follow

The earliest effects most people notice are appetite-related rather than weight-related. Semaglutide works by mimicking GLP-1, a gut hormone involved in signalling fullness to the brain and slowing how quickly the stomach empties. Even at 0.25 mg, those signals shift. Portions that felt normal start feeling like enough. The pull towards snacking between meals lessens. Some people describe eating less simply because they stop earlier, without actively trying. These changes can appear within days of the first injection.

Measurable weight change tends to follow a few weeks behind that appetite shift. By around weeks eight to twelve (for many people now on the 1.0 mg dose) modest weight reduction is usually visible on the scales. The rate increases as the dose does. By six months on maintenance dose, the pattern of response is clearer. More detail on the early-weeks timeline is available if you want a closer look at those first 12 weeks specifically.

The STEP 1 trial, published in the New England Journal of Medicine, followed adults taking 2.4 mg semaglutide for 68 weeks alongside lifestyle changes. Average weight loss was approximately 15% of starting body weight. That figure represents an endpoint after well over a year, not a six-week result, which is an important context that often gets lost.

Why some people notice results sooner than others

Response to Wegovy is genuinely variable, and several things influence how quickly changes become noticeable. Starting weight plays a role: someone carrying significantly more weight may see larger absolute numbers move earlier, even if the percentage change is similar. How consistently doses are taken, whether meals are adjusted alongside treatment, activity levels, sleep quality and individual metabolic factors all contribute. There is also the question of which outcome you're measuring, appetite and energy levels often shift before the scales do, and some people notice those changes clearly while others are less aware of them.

The dose itself is the most predictable variable. People who tolerate the escalation well and reach 2.4 mg (or the newer 7.2 mg option, details on the Wegovy updates page) without prolonged pauses at lower doses tend to see stronger effects sooner. Those who need to stay at a lower dose for longer (for comfort or clinical reasons) will have a slower trajectory, which is entirely appropriate clinically. A prescriber's job is to match the pace of titration to your individual tolerance, not to rush it.

If you're comparing notes with someone else on the same treatment and your timelines differ, that's normal. It doesn't mean the medicine isn't working for you.

When to raise a concern, and what doesn't warrant one

Not losing weight after two weeks is not a concern. Not losing weight after eight weeks at 0.25 mg or 0.5 mg is also, broadly, expected. Losing less than 5% of body weight after six months at your highest tolerated maintenance dose is the point at which your prescriber would review whether continuing makes clinical sense, that threshold is the one used in NICE guidance on weight-loss medicines, including semaglutide.

What does warrant prompt attention is anything from the safety side: severe or persistent stomach pain, especially pain that radiates to the back, should be assessed urgently given the established association with acute pancreatitis, the MHRA's Yellow Card scheme is the right place to report suspected side effects, and your prescriber should be contacted directly. Dehydration from persistent vomiting or diarrhoea, signs of an allergic reaction, or anything that feels serious should be acted on quickly, not waited out. The NHS patient information for semaglutide lists the symptoms to watch for in plain language.

For everything else (slower-than-expected weight loss, hunger returning on a particular day, a week where nothing changes) the answer is usually continued patience and a conversation with your prescriber at the next review. At nume, that review happens before every repeat order, so there's a structured point at which to raise it. If you'd like to discuss your options with a GPhC-registered prescriber, starting a free consultation is the first step.